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INTRODUCTION
Coronavirus disease 2019 (COVID-19) is the clinical mani-
festation of the pandemic infection caused by a positive-sense 
RNA virus named the severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2), initially described in Wuhan, 
China (Table 1 for abbreviations).(1) SARS-CoV-2 forms a 
clade within the subgenus sarbecovirus, subfamily Orthocoro-
navirinae. Different from both MERS-CoV and SARS-CoV, 
2019-nCoV (or SARS-CoV-2) is the seventh member of the 
family of coronaviruses that infect humans.(2) Common symp-
toms of COVID-19 are fever, breathlessness, fatigue and dry 
cough. In addition, patients may report headaches, myalgia, 
nasal congestion, rhinorrhoea, anosmia, sore throat or diar-
rhoea. Symptoms are usually mild, many are infected but 
remain asymptomatic, and over 80% recover from COVID-19 
without special treatment. Those at risk of severe illness and 
hospitalisation include those with multimorbidity, obesity, 
hypertension, cardiovascular disease (CVD), lung disease, can-
cer, diabetes and the elderly.(2,3)
SARS-CoV-2 infects host cells through the angiotensin-
converting enzyme type 2 (ACE2) receptors, leading to 
COVID-19.(4) COVID-19 is transmitted through small droplets 
and may be airborne from the nose or mouth during speech, 
exhalation, singing, laughing and coughing. Incubation period 
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Angiotensin converting enzyme inhibitors (ACE-Is), 
angiotensin receptor blockers (ARBs) and mineralo-
corticoid receptor antagonists (MRAs) reduce mor-
bidity, mortality and hospitalisations from hypertension, 
chronic kidney disease and heart failure. Patients and 
clinicians will be aware of the recently publicised 
interaction between the renin-angiotensin-aldosterone 
system (RAAS) and SARS-CoV-2, the orthocoronavirus 
responsible for coronavirus disease 2019 (COVID-19). 
Consequently, concern has abounded in regard to 
whether prescribed blockers of the RAAS like ACE-Is, 
ARBs and MRAs may, in fact, increase or decrease 
susceptibility to SARS-CoV-2 infection. Limited scien-
tifi c evidence has been contradictory. Scientists have 
postulated both potentially harmful and potentially 
benefi cial effects of these drugs on the natural history 
of COVID-19. Membrane-bound angiotensin-converting 
enzyme 2 (ACE2) participates in the entry of SARS-
CoV-2 into human cells, and animal studies show that 
ACE-Is and ARBs upregulate ACE2 expression, which 
would theoretically increase risk for or severity of 
COVID-19. Conversely, RAAS blockers could benefi t 
patients with COVID-19 through various mechanisms: 
ACE2 converts angiotensin II to angiotensin, which has 
potentially benefi cial vasodilatory and anti-infl am-
matory properties. Observational studies have failed to 
provide compelling data on whether COVID-19 patients 
on RAAS blockers fare better or worse than otherwise 
similar patients, though there is emerging evidence that 
RAAS inhibitors may be protective in COVID-19 and 
are associated with lower cardiovascular and all-cause 
mortality. Most professional societies, including the 
World Health Organization and the South African 
Heart Association and the South African National 
Department of Health have recommended that patients 
on RAAS blockers with COVID-19 should continue 
taking them. In this article, we review the existing 
evidence for the interplay between RAAS blockers and 
SARS-CoV-2 infection.  SAHeart 2020;17:352-361
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for COVID-19 ranges from 1 - 14 days, commonly around 5 
days; asymptomatic individuals may still transmit the virus.(5)
RENIN-ANGIOTENSIN-ALDOSTERONE 
SYSTEM AND ITS INHIBITORS
The renin-angiotensin-aldosterone system (RAAS) plays a 
central role in regulating blood volume and systemic vascular 
resistance (SVR), which together influence cardiac output/
stroke volume and blood pressure (BP) – Figure 1. Renin, which 
is released primarily by the kidneys, stimulates the formation of 
angiotensin in blood and tissues, which in turn stimulates the 
release of aldosterone from the adrenal cortex.(6) Renin is a 
proteolytic enzyme that is released into the circulation by the 
kidneys, as a consequence of: (i) sympathetic nerve activation, 
through β1-adrenoceptors; (ii) renal artery hypotension from 
systemic hypotension or renal artery stenosis; and (iii) decreased 
sodium delivery to the distal tubules of the kidney. When renin 
is released into the blood, it acts upon a circulating sub-
strate, angiotensinogen, that undergoes proteolytic cleavage to 
form the decapeptide angiotensin-(1-7). Vascular endothelium, 
particularly in the lungs, has an enzyme, angiotensin converting 
enzyme (ACE) that cleaves off two amino acids to form the 
octapeptide, angiotensin II (AII), although many other tissues in 
the body (heart, brain, vascular) also can form AII(7) – Table 2 
summarises the important role of the RAAS in human 
physiology. RAAS is not only regulated by the mechanisms that 
stimulate renin release, but is also modulated by natriuretic 
peptides released by the heart,(8) which act as an important 
counter-regulatory system (Figure 1). Therapeutic manipulation 
of the RAAS is important for management of hypertension, 
kidney disease, heart failure and diabetes, through use of RAAS 
blockers, which decrease arterial BP, ventricular afterload, 
blood volume and hence ventricular preload, as well as inhibit 
and reverse cardiac and vascular hypertrophy (Figure 2).(9)
COVID-19 AND HYPERTENSION
Increased mortality and morbidity of COVID-19 in patients 
with hypertension has been observed in several initial 
epidemiological studies outlining the characteristics of the 
COVID-19 epidemic in China. In a study of 201 patients 
confirmed to have SARS-CoV-2 infection, hypertension was 
reported to have a hazard ratio (HR) of 1.70 for death and 1.82 
for acute respiratory distress syndrome.(10) In a separate study 
of 191 patients with COVID-19, hypertension reportedly had a 
HR of 3.05 for in-hospital mortality.(11) However, neither of 
these studies(10,11)  adjusted for confounding variables, and the 
validity of the association of poor outcomes with hyperten-
sion remains unclear. In the largest case series from China, 
hypertension was the most frequent coexisting condition in 
1 099 patients, with an estimated prevalence of 15%,(12) though 
this estimate is lower than the estimated prevalence of hyper-
tension seen with other viral infections,(13) and in the general 
population in China,(14) or other parts of the world.(15)
Coexisting conditions, including hypertension, have consistently 
been reported to be more common among patients with 
COVID-19 who have had severe illness, been admitted to the 
intensive care unit, received mechanical ventilation, or died, 
compared to patients who have had mild illness. Concerns 
have been raised that medical management of coexisting con-
ditions, including the use of RAAS blockers, may have con-
tributed to the adverse health outcomes observed; however, 
these conditions track closely with advancing age, which is 
emerging as the strongest predictor of COVID-19 related 
TABLE I: Abbreviations.
ACE 2 Angiotensin converting enzyme type 2
ACE-Is Angiotensin converting enzyme inhibitors
ARBs Angiotensin receptor blockers
BP Blood pressure
COVID-19 Coronavirus disease 2019
CVD Cardiovascular disease
MRAs Mineralocorticoid receptor antagonists
RAAS Renin-angiotensin-aldosterone system
SARS-CoV-2
Severe acute respiratory syndrome 
coronavirus 2
SVR Systemic vascular resistance
TABLE II: Roles of RAAS in human physiology.
Constricts resistance vessels via AII and ATI receptors, thereby increasing 
SVR and BP.
Stimulates sodium reabsorption at multiple renal tubular sites, thereby 
increasing sodium and water retention.
Acts on adrenal cortex to release aldosterone, which acts on kidneys to 
promote sodium and water retention.
Stimulates release of vasopressin (antidiuretic hormone – ADH) from 
the posterior pituitary, thereby increasing fl uid retention by the kidneys.
Stimulates thirst centres in the brain, thereby increasing fl uid intake.
Facilitates noradrenaline release from sympathetic nerve endings and 




Release of ADH increases cardiac output.
Enhances potassium excretion in the urine.
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death.(16) To date, most of the published reports have not 
rigorously accounted for age or other risk factors as potential 
confounders for risk prediction. Data showing patterns of 
use of RAAS blockers and associated health outcomes that 
rigorously account for treatment indication and illness severity 
among patients with COVID-19, are urgently needed.
The association between hypertension and COVID-19 mor-
bidity and mortality has been linked to the ACE2 upregulation 
and RAAS blocker use, severe hypokalaemia associated with 
COVID-19 infection in one study,(17) and immune dysregulation 
in the setting of poorly controlled hypertension.(18) The under-
standing of these mechanisms and their effect on hypertension 
as a predictor of morbidity and mortality is still to be determined. 
BIOLOGY OF ACE2
Given its centrality to viral entry (Figure 3) and mechanism of 
action of RAAS blockers, the biology of ACE2 warrants con-
sideration. The putative link between angiotensin converting 
enzyme inhibitors (ACE-Is), angiotensin receptor blockers 
(ARBs) and mineralocorticoid receptor antagonists (MRAs) and 
SARS-CoV-2, is predicated on the understanding that ACE2 
is the co-receptor for viral entry for SARS-CoV-2, and has a 
critical role in the pathogenesis of COVID-19. ACE2 has a 
broad expression pattern in the human body with strong 
expression noted in the heart, kidneys, lungs, and gastroin-
testinal system. These common areas of expression of ACE2 
are extrapolated from ACE2 activity levels in mice, with the 
highest level of expression in the gastrointestinal tract and 
kidneys, followed by the heart and lungs. Recent studies in 
human models show discordance between mice models on 
the protein expression, activity and mRNA levels of ACE2 in 
various parts of the human body, proving that the delicate 
physiological balance of the components of RAAS is not yet 
fully understood.(12,13) Fears about RAAS blockers and poor 
outcomes in COVID-19 are due to a suggestion that ACE-Is 
directly inhibits ACE2; however, ACE2 functions as a car-
boxypeptidase and is not inhibited by clinically prescribed 
FIGURE 1: Renin-angiotensin-aldosterone system.
ACE = angiotensin converting enzyme, ADH = antidiuretic hormone.






















































ACE-Is;(5) there is also a concern that the use of RAAS blockers 
increases expression of ACE2 and may increase patient sus-
ceptibility to viral host cell entry and propagation; however, 
there is limited evidence showing changes in serum or pul-
monary ACE2 levels. Importantly, the signif icance of ACE2 
expression on COVID-19 pathogenesis and mortality is 
unknown.(19,20)
ACE2 primarily acts to counterbalance the effect of ACE. As 
ACE generates AII from angiotensin I, ACE2 generates angio-
tensin-(1-7) from AII, which shifts the balance from vasoconstric-
tion with AII to vasodilation with Mas receptor activation in 
the effected vascular bed. The role this vasodilatory effect has 
in the pathogenesis of COVID-19 is unclear, but some animal 
data suggests a link.(21) 
INTERACTIONS OF RAAS BLOCKERS 
AND ACE2
AII activates type I angiotensin receptors (AT1) and type II 
angiotensin receptors (AT2) resulting in a series of events that 
either promote inflammation, vasoconstriction or atherogenesis 
through AT1 receptor pathway or the opposite: vasodilation, 
decreased platelet aggregation and promotion of insulin action 
through the AT2 pathway.(22,23) AII is converted into angio-
tensin-(1-7) indirectly by ACE2, producing similar effects to the 
AT2 pathway due to normal expression of AT2 in adults being 
low. Conceptualising the intricate balance of the Ang II/
AT1receptor and its opposing pathway ACE2/Ang-(1-7) and its 
effects (Figure 4) helps with understanding the consequences 
of imbalance and how the use of RAAS blockers may play a 
role in this intricate system.(24) Angiotensin converting enzyme 
inhibitors (ACE-Is) have a partial effect by decreasing the 
conversion of angiotensin I (Ang-1) to angiotensin II (Ang-2) 
and ACE levels are decreased through negative feedback in 
the presence of high AII levels. Angiotensin receptor blockers 
(ARBs) increase AII levels available for redirection through the 
anti-inflammatory AT2 pathway.(24) Circulating levels of soluble 
ACE2 are low and the functional role of ACE2 in the lungs and 
heart appears to be minimal under normal conditions,(25,26) but 
FIGURE 2: Mechanisms of action of RAAS blockers.






















FIGURE 4: Counter-regulatory effects of angiotensin II receptor type 1 and angiotensin II receptor type II pathways.
Renin-angiotensin-aldosterone system in patients with COVID-19. 
ACEi = angiotensin converting enzyme inhibitor, ACE1 = angiotensin converting enzyme, ACE2 = angiotensin converting enzyme 2, ARB = angiotensin receptor blocker, 
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FIGURE 3: Interaction of SARS-CoV-2 and RAAS blockers.
ACE = angiotensin converting enzyme, ACE2 = angiotensin converting enzyme 2, AT1R = type 1 angiotensin II receptor, AT2R = type 2 angiotensin II receptor.
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may be up-regulated in certain clinical states. Because different 
RAAS blockers have variable effects on AII, the primary 
substrate of ACE2, the effects of these agents on ACE2 levels 
and activity may be anticipated to differ. Despite substantial 
structural homology between ACE and ACE2, their enzyme 
active sites are distinct; therefore ACE-Is in clinical use do not 
directly affect ACE2 activity.(27) Animal models have shown 
conflicting evidence of the impact of ACE-Is and ARBs on 
ACE2 levels.(13,28-30) In human studies, RAAS blockers did not 
influence angiotensin production (1-7), a finding that calls into 
question whether ACE-Is have any direct effects on ACE2-
directed AII metabolism.(31,32) Furthermore, in studies of heart 
failure,(28)  atrial fibrillation,(33)  aortic stenosis(34)  and coronary 
artery disease,(35) plasma ACE2 activity was not higher among 
patients who were taking ACE-Is or ARBs compared to 
untreated patients. However, in one study of patients with 
hypertension, urinary ACE2 levels were higher in patients who 
received long-term treatment with the ARB, olmesartan, than 
in untreated control patients, but that association was not 
observed with the ACE-I, enalapril, or with other ARBs 
(losartan, candesartan, valsartan, and telmisartan).(36)
The conflicting data above reinforces the concept that findings 
from preclinical models may not readily translate to human 
physiology. Therefore, effects on ACE2 should not be assumed 
to be uniform across RAAS inhibitors or even in response to 
therapies within a given drug class.(36) Importantly, plasma ACE2 
levels may not be a reliable indicator of the activity of the full-
length membrane-bound form, in part because ACE2 is shed 
from the membrane, a process that appears to be separately 
regulated by an endogenous inhibitor, and biologic relevance of 
ACE2 may vary according to tissue and clinical state.(37) There is 
an urgent and critical need for further human mechanistic 
studies to better define the unique interplay between SARS-
CoV-2 and the RAAS network. The use of short and long-term 
use of RAAS blockers should be investigated as the effects on 
ACE2 levels appear to be variable, with low to normal levels 
with short-term use and mildly elevated levels with longer 
term use.(12)
EVIDENCE FOR BENEFIT OF RAAS BLOCKERS 
IN COVID-19
In an animal model, ACE2 downregulation by SARS-CoV 
worsened lung injury that was improved by treatment with an 
ARB.(38) However, there is no direct clinical evidence that has 
proven ACE2 to be an effective treatment for viral-induced 
lung injury. A preliminary trial of ACE2 infusion in 10 patients 
with acute respiratory distress syndrome (ARDS) was com-
pleted in humans, but was not powered to show efficacy on 
pulmonary function.(39) Downregulation of ACE2 activity in the 
lungs facilitates the initial neutrophil infiltration in response to 
bacterial endotoxin,(40) and may result in unopposed AII accu-
mulation and local RAAS activation. Indeed, in experimental 
mouse models, exposure to SARS-CoV-1 spike protein induced 
acute lung injury, which is limited by RAAS blockade.(40) 
COVID-19 patients had elevated levels of plasma AII, which 
were in turn correlated with total viral load and degree of 
lung injury,(41) and restoration of ACE2 through the admini-
stration of recombinant ACE2 reversed this devastating lung-
injury process in preclinical models of other viral infections,(42,43) 
and safely reduced AII levels in a phase 2 trial evaluating ARDS 
in humans.(39) 
Recently, inpatient use of ACE-Is and ARBs in patients with 
COVID-19 was associated with lower mortality in hospitalised 
patients with known CVD, with an adjusted HR of 0.42.(44) In 
a study of 1 139 COVID-19 patients receiving ACE-Is and 
ARBs, there was no signal for harm from the use of RAAS 
inhibitors.(45) Of 19 486 patients with COVID-19, 1 286 were 
admitted to the intensive care unit. ACE-Is and ARBs were 
associated with reduced risk of COVID-19, but had no impact 
on admission to intensive care after adjusting for a wide range 
of confounders.(16) Finally, with a retrospective cohort of 4 480 
patients with COVID-19, with 20% of these receiving either 
an ACE-I or an ARB, RAAS blocker use was not associated 
with increased risk of contracting COVID-19, COVID-19 
disease severity, or COVID-19 mortality.(46) 
POTENTIAL HARM FROM USE OF RAAS 
BLOCKERS IN COVID-19
Abnormal regulation of ACE2 may theoretically attenuate 
cardioprotection in the context of myocardial involvement 
and abnormal pulmonary haemodynamics  in COVID-19.(47,48) 
Markers of myocardial injury are demonstrably elevated during 
the course of COVID-19,(49) and increase rapidly with clinical 
deterioration and preceding death.(11) As many viruses are 
cardiotropic, subclinical viral myocarditis is commonly seen in 
viraemia associated with a wide range of infectious agents. 
ACE2 plays an important role in myocardial recovery and injury 
response. For instance, ACE2 knockout animal models resulted 
in adverse left ventricular remodelling in response to acute 
injury driven by A II.(50) Autopsies of patients who died from 
SARS showed that 35% of heart samples had presence of viral 
RNA and reduced ACE2 protein expression.(51) Furthermore, 
administration of recombinant ACE2 normalises AII levels in 
human explanted hearts in dilated cardiomyopathy.(52) 
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Additionally, despite these theoretical uncertainties regarding 
whether pharmacologic regulation of ACE2 may influence 
the infectivity of SARS-CoV-2, there is clear potential for 
harm related to the withdrawal of RAAS blockers in patients 
with heart failure and chronic kidney disease, in an otherwise 
stable condition. COVID-19 is particularly severe in patients 
with underlying CVD,(1) and in many patients, active myo-
cardial injury,(11,53-55) myocardial stress,(54) and cardiomyopathy(54) 
develop during the course of illness. RAAS inhibitors have 
established benefits in protecting the kidney and myocardium, 
and their withdrawal may risk clinical decompensation in high-
risk patients.
GUIDANCE FOR CLINICIANS ON USE OF 
RAAS INHIBITORS IN PATIENTS WITH 
COVID-19
Despite the lack of evidence, there have been advocates for 
both the use and cessation of ACE-Is, ARBs, and/or MRAs 
during the treatment of COVID-19 in patients with hyper-
tension, heart failure and coronary artery disease, prompting 
some patients to solicit changes in their CVD medications and 
growing the uncertainty from physicians on what should be 
done. Changes in CVD medications require patients to visit 
their physician/cardiologist, pharmacy and possibly obtain 
blood work, which would increase their exposure and risk of 
infection from SARS-CoV-2 during the pandemic. Antihyper-
tensive medication changes between classes additionally re-
quires frequent dose adjustment and management of adverse 
effects and increases the risk of medical errors. Consequently, 
the World Health Organization,(56) the European Medicines 
Agency,(57) and the South African National Department of 
Health(58) statements on RAAS blocker used in COVID-19, all 
advise against stopping ACE-Is or ARBs unless there is a 
compelling reason, other than COVID-19, to do so.
The Council on Hypertension of the European Society of 
Cardiology made the following statement: “The Council on 
Hypertension strongly recommends that physicians and patients 
should continue treatment with their usual anti-hypertensive 
therapy because there is no clinical or scientific evidence to 
suggest that treatment with ACE-Is or ARBs should be dis-
continued because of the COVID-19 infection.”(59) This state-
ment has been followed by similar statements from a number 
of different societies suggesting patients continue their current 
hypertensive medication regimen. The American Heart Asso-
ciation, the Heart Failure Society of America, and the American 
College of Cardiology announced a joint statement advocating 
for patients to continue ACE-Is and ARBs as prescribed and 
that changes in medications in the setting of COVID-19 should 
be completed only after careful assessment.(60) 
On the basis of available evidence, we think that, despite the 
theoretical concerns regarding the effect of RAAS inhibitors 
on ACE2 and the way in which these drugs may affect the 
propensity for severe COVID-19 disease, RAAS blockers 
should be continued in patients in otherwise stable condition 
who are at risk for, are being evaluated for, or have confirmed 
COVID-19. Furthermore, there is now compelling evidence of 
lack of harm and some evidence for benefit of use of RAAS 
blockers in COVID-19 (Table 3).
CONCLUSIONS
ACE-Is, ARBs and MRAs reduce morbidity, mortality and 
hospitalisations from hypertension, chronic kidney disease, 
heart failure and coronary artery disease. In recent months, 
there has been increased concern about the use of RAAS 
blockers in patients with COVID-19. Existing limited animal and 
human evidence has been contradictory, but overall, largely 
showing lack of harm and some evidence of protection from 
RAAS blockers in hospitalised COVID-19 patients. Membrane-
bound angiotensin-converting enzyme 2 (ACE2) participates in 
the entry of SARS-CoV-2 into human cells, and animal studies 
show that ACE-Is and ARBs upregulate ACE2 expression, 
which would theoretically increase risk for or severity of 
COVID-19. Conversely, RAAS blockers could benefit patients 
with COVID-19 through various mechanisms: ACE2 con-
TABLE III: Key take-home messages.
Hypertension and other CVD are over-represented among people who 
develop the most severe complications of COVID-19.
SARS-CoV-2 enters cells by utilising ACE2 and type II transmembrane 
serine proteases (TMPRSS2).
ACE2 is most expressed in the cardiovascular system, gastrointestinal tract, 
kidneys and lungs; in the cardiovascular system, ACE2 is expressed in the 
cardiomyocytes, epicardial adipose tissue, cardiac fi broblasts, vascular 
smooth muscle and endothelial cells.
ACE2 is an enzyme that physiologically counters RAAS activation.
Select preclinical studies have suggested that RAAS blockers may increase 
ACE2 expression, raising concerns regarding their safety in patients with 
COVID-19. Insuffi cient data are available to determine whether these 
observations readily translate to humans. Existing data suggests a lack of 
harm. Clinical trials are under way to test the safety and effi cacy of RAAS 
modulators, including recombinant human ACE2 and the ARB losartan in 
COVID-19.
Abrupt withdrawal of RAAS inhibitors in high-risk patients, including those 
who have heart failure or have had myocardial infarction, may result in 
clinical instability and adverse health outcomes.
Until further data are available, we recommend that RAAS inhibitors 
should be continued in patients in otherwise stable condition, who are at 













verts AII to angiotensin-(1-7), which has potentially beneficial 
vasodilatory and anti-inflammatory properties. Observational 
studies have failed to provide compelling data on whether 
COVID-19 patients on RAAS blockers fare worse than 
otherwise similar patients. 
The lack of definitive evidence on the use of RAAS blockers in 
COVID-19 provides an opportunity for the research commu-
nity to better outline the RAAS and specifically the role of 
ACE2 in the pathogenesis of COVID-19, while clinical data are 
accumulated to determine if there is a link between the use of 
RAAS blockers and COVID-19 mortality and morbidity. Until 
more substantial data is available to guide decision-making, 
physicians should be available to listen to patients’ concerns 
and provide reassuring advice about RAAS blocker medica-
tions in the era of the COVID-19 pandemic. Most professional 
societies have recommended that patients on RAAS blockers 
with COVID-19 should continue taking these drugs for their 
benefits in treating the underlying disease.
ACKNOWLEDGEMENTS
The figures have been created using Biorender® software. 
FUNDING
This article is not funded. Ntobeko Ntusi gratefully acknowl-
edges funding from the National Research Foundation, Medical 
Research Council of South Africa and the Lily and Ernst 
Hausmann Trust.
Conflict of interest: none declared.
REFERENCES
1.  Wu  Z, McGoogan  JM. Characteristics of and important lessons from the 
coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a 
report of 72 314 cases from the Chinese Center for Disease Control and 
Prevention. JAMA 2020;323:1239-1242.
2.  Ntusi NAB. COVID-19 and cardiovascular disease. S Afr Heart J 2020;
17:10-13. 
3.  Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, 
comorbidities and outcomes among 5 700 patients hospitalised with 
COVID-19 in the New York City Area. JAMA 2020;323:2052-2059.
4.  Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with 
a new coronavirus of probable bat origin. Nature 2020;579:270-273. 
5.  Aarons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 
infections and transmission in a skilled nursing facility. N Engl J Med 2020;
382:2081-2090.
6.  Carey RM, Padia SH. Chapter 1 – Physiology and regulation of the renin-
angiotensin-aldosterone system. In: Singh AK, Williams GH (eds). Textbook 
of Nephro-Endocrinology (second edition). Amsterdam: Elsevier; 2017:1-25.
7.  Metzger R, Wagner D, Takahashi S, et al. Clin Exp Hypertens 2017;
10:1227-1238.
8.  Volpe M, Carnovali M, Moastromarino V. The natriuretic peptides system 
in the pathophysiology of heart failure: From molecular basis to treatment. 
Clin Sci 2016;130:57-77.
9.  Ferrario CM, Mullick AE. Renin angiotensin aldosterone inhibition in the 
treatment of cardiovascular disease. Pharmacol Res 2017;125(Pt A):57-71.
10.  Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory 
distress syndrome and death in patients with coronavirus disease 2019 
pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934-943.
11.  Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of 
adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort 
study. Lancet 2020;395:1054-1062.
12.  South AM, Diz DI, Chappell MC. COVID-19, ACE2 and consequences. 
Am J Physiol Heart Circ Physiol 2020;318:H1084-H1090. 
13.  Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system 
blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney 
Int 2005;68:2189-2196.
14.  Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: Results 
from the China Hypertension Survey 2012-2015. Circulation 2018;137:
2344-2356.
15.  Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat 
Rev Nephrol 2020;16:223-237.
16.  Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 
disease with ACE inhibitors and angiotensin receptor blockers: cohort study 
including 8.3 million people. Heart 2020;106:1503-1511.
17.  Chen D, Li X, Song Q, et al. Assessment of hypokalaemia and clinical 
characteristics in patients with coronavirus disease 2019 in Wenzhou, China. 
JAMA Network Open 2020;3:e2011122.
18.  Li D, Chen Y, Jia Y, et al. SARS-CoV-2-induced immune dysregulation and 
myocardial injury risk in China: Insights from the ERS-COVID-19 study. Circ 
Res 2020;127:397-399.
19.  Messerli FH, Siontis GCM, Rexhaj E. COVID-19 and renin angiotensin 




20.  Bai F, Xue-Fen P, Li-Hui Z, et al. Angiotensin II AT1 receptor alters ACE2 
activity, eNOS expression and CD44-hyaluronan interaction in rats with 
hypertension and myocardial fibrosis. Life Sciences 2016;153:141-152.
21. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers. What is the evidence? JAMA 2020;
323:1769-1770.
22.  Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular 
system: Implications for risk assessment, diagnosis, and treatment options. 
Cardiovasc Res 2020;116:1666-1687.
23. Ingraham NE, Barakat AG, Reilkof R, et al. Understanding the renin-
angiotensin-aldosterone-SARS-CoV-axis: A comprehensive review. Eur 
Respir J 2020;56:2000912. 
24.  Dandona P, Dhindsa S, Ghanim H, et al. Angiotensin II and inflammation: 
The effect of angiotensin-converting enzyme inhibition and angiotensin II 
receptor blockade. J Hum Hypertens 2007;21:20-27.
25.  Igase M, Strawn WB, Gallager PE, et al. Angiotensin II AT1 receptors regulate 
ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously 
hypertensive rats. Am J Physiol Heart Circ Physiol 2005;289(3):H1013-H1019.
26.  Burchill LJ, Velkoska E, Dean RG, et al. Combination renin-angiotensin 
system blockade and angiotensin-converting enzyme 2 in experimental 
myocardial infraction: Implications for future therapeutic directions. Clin Sci 
(Lond) 2012;123(11):649-658.
27.  Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting 
enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide 
metabolism. Biochem J 2004;383(Pt 1):45-51. 
28. Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of 
angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction 
in myocardial infarcted rat. Hypertension 2006;48:572-578.
29. Sukumaran V,  Tsuchimochi H,  Tatsumi E, et al. Azilsartan ameliorates 
diabetic cardiomyopathy in young db/db mice through the modulation of 
ACE-2/ANG 1-7/Mas receptor cascade. Biochem Pharmacol  2017;
144:90-99.
30. Sukumaran V, Veeraveedu PT, Gurusamy N, et al. Cardioprotective effects 
of telmisartan against heart failure in rats induced by experimental auto-
immune myocarditis through the modulation of angiotensin-converting 
enzyme-2/angiotensin 1-7/mas receptor axis. Int J Biol Sci 2011;7:1077-1092.
31. Campbell DJ,  Zeitz CJ,  Esler MD,  et al. Evidence against a major role 
for angiotensin converting enzyme-related carboxypeptidase (ACE2) in 
angiotensin peptide metabolism in the human coronary circulation. 
J Hypertens 2004;22:1971-1976.
32.  Luque M, Martin P, Martell N, et al. Effects of captopril related to increased 
levels of prostacyclin and angiotensin-(1-7) in essential hypertension. 
J Hypertens 1996;14:799-805.
33.  Walters TE,  Kalman JM,  Patel SK, et al. Angiotensin converting enzyme 2 
activity and human atrial fibrillation: Increased plasma angiotensin converting 
enzyme 2 activity is associated with atrial fibrillation and more advanced 
left atrial structural remodelling. Europace 2017;19:1280-1287.
34.  Ramchand J,  Patel SK,  Kearney LG, et al. Plasma ACE2 activity predicts 
mortality in aortic stenosis and is associated with severe myocardial fibrosis. 
JACC Cardiovasc Imaging 2020;13:655-664.
35. Ramchand J,  Patel SK,  Srivastava PM,  et al. Elevated plasma angiotensin 
converting enzyme 2 activity is an independent predictor of major adverse 
cardiac events in patients with obstructive coronary artery disease. PLoS 
One 2018;13(6):e0198144.
36.  Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensin-converting enzyme 
2 in hypertensive patients may be increased by olmesartan, an angiotensin II 
receptor blocker. Am J Hypertens 2015;28:15-21.
37.  Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-α convertase 
(ADAM17) mediates regulated ectodomain shedding of the severe-acute 
respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-con-
verting enzyme-2 (ACE2). J Biol Chem 2005;280:30113-30119.
38.  Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 
2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;
11:875-879. 
39.  Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human 
angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit 
Care 2017;21(1):234.
40.  Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, et al. Attenuation of pulmonary 
ACE2 activity impairs inactivation of des-Arg bradykinin/BKB1R axis and 
facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol 
Physiol 2018;314:L17-L31.
41.  Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-
nCoV infected patients linked to viral loads and lung injury. Sci China Life 
Sci 2020;63:364-374.
42.  Zou Z, Yan Y, Shu Y, et al. Angiotensin-converting enzyme 2 protects from 
lethal avian influenza A H5N1 infections. Nat Commun 2014;5:3594-3594.
43.  Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits lung injury 
induced by respiratory syncytial virus. Sci Rep 2016;6:19840.
44.  Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-
converting enzyme inhibitors and angiotensin II receptor blockers with 
mortality among patients with hypertension hospitalised with COVID-19. 
Circ Res 2020;126:1671-1681. 
45.  De Abajo FJ, Rodriguez-Martin S, Lerma V, et al. Use of renin-angiotensin-
aldosterone system inhibitors and risk of COVID-19 requiring admission 
to hospital: A case-population study. Lancet 2020;395:1705-1714.
46.  Fosbol EL, Butt JH, Ostergaard L, et al. Association of angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diag-
nosis and mortality. JAMA 2020;342:168-177.
47.  Hemnes AR, Rathinasabapathy A, Austin EA, et al. A potential therapeutic 
role for angiotensin-converting enzyme 2 in human pulmonary arterial 
hypertension. Eur Respir J 2018;51:1702638.
48.  Tan WSD,  Liao W, Zhou S, et al. Targeting the renin-angiotensin system 
as novel therapeutic strategy for pulmonary diseases. Curr Opin 
Pharmacol 2018;40:9-17.
49.  Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in 
hospitalised patients with COVID-19 in Wuhan, China. JAMA Cardiol 
2020;5:802-810.
50.  Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting enzyme 2 
accelerates maladaptive left ventricular remodeling in response to myo-
cardial infarction. Circ Heart Fail 2009;2:446-455.
51.  Oudit GY,  Kassiri Z,  Jiang C, et al. SARS-coronavirus modulation of 
myocardial ACE2 expression and inflammation in patients with SARS. Eur J 
Clin Invest 2009;39:618-625.
52. Basu R, Poglitsch M, Yogasundaram H, et al. Roles of angiotensin peptides 
and recombinant human ACE2 in heart failure. J Am Coll Cardiol  2017;
69:805-819.














53.  Ruan Q,  Yang K,  Wang W, et al. Clinical predictors of mortality due to 
COVID-19 based on an analysis of data of 150 patients from Wuhan, China. 
Intensive Care Med 2020;46:846-848. 
54.  Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill 
patients with COVID-19 in Washington State. JAMA 2020;323:1612-1614.
55.  Wang D,  Hu B,  Hu C, et al. Clinical characteristics of 138 hospitalised 
patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. 
JAMA 2020;323:1061-1069.
56.  World Health Organization. COVID-19 and the use of angiotensin-
converting enzyme inhibitors and receptor blockers. World Health 
Organization 2020. Retrieved on June 24, 2020: https://www.who.int/news-
room/commentaries/detail/covid-19-and-the-use-of-angiotensin-converting-
enzyme-inhibitors-and-receptor-blockers.
57.  European Medicines Agency. Latest data support continued use of ACE 
inhibitors and ARB medicines during COVID-19 pandemic. European 
Medicines Agency 2020. Retrieved on June 24, 2020: https://www.ema.
europa.eu/en/news/latest-data-support-continued-use-ace-inhibitors-arb-
medicines-during-covid-19-pandemic.
58. South African National Department of Health/National Institute for 
Communicable Diseases. Clinical management of suspected or confirmed 
COVID-19 disease. Version 4 (26th April 2020). National Institutes for 
Communicable Disease 2020. Retrieved on June 24, 2020: https://www.nicd.
ac.za/diseases-a-z-index/covid-19/covid-19-guidelines/clinical-management-
of-suspected-or-confirmed-covid-19-disease/.
59.  European Society of Cardiology. Position statement of the ESC Council 
on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 
Published March 13, 2020. Retrieved on May 31, 2020: https://www.escardio.
org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-
of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang.
60.  American Heart Association. HFSA/ACC/AHA statement addresses con-
cerns re: Using RAAS antagonists in COVID-19. Retrieved on May 31, 2020: 
https://professional.heart.org/professional/ScienceNews/UCM_505836_
HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-
in-COVID-19.jsp.
